(Q41662628)

6 October 2017

1 reference

title

Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock (English)

1 reference

6 October 2017

Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock (English)

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

28 November 2024

0 references

1 reference

1

Dinarello CA

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

6 October 2017

December 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9400897

full work available at URL

28 November 2024

https://api.elsevier.com/content/article/PII:S0012369215437158?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

https://api.elsevier.com/content/article/PII:S0012369215437158?httpAccept=text/plain

28 November 2024

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

28 November 2024

1 reference

6 October 2017

volume

112

1 reference

6 October 2017

issue

6 Suppl

1 reference

6 October 2017

page(s)

321S-329S

1 reference

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies

6 October 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer

28 November 2024

3

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Activation of coagulation after administration of tumor necrosis factor to normal subjects

28 November 2024

4

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta

28 November 2024

8

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin 1 alpha causes rapid activation of cytosolic phospholipase A2 by phosphorylation in rat mesangial cells

28 November 2024

9

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Cloning of a phospholipase A2-activating protein

28 November 2024

10

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin 1 alpha activates two forms of p54 alpha mitogen-activated protein kinase in rabbit liver

28 November 2024

11

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Specific activation of beta-casein kinase by the inflammatory cytokines interleukin 1 and tumour necrosis factor

28 November 2024

12

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27.

28 November 2024

13

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Nitric oxide: physiology, pathophysiology, and pharmacology

28 November 2024

15

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat renal mesangial cells

28 November 2024

16

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo

28 November 2024

17

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

28 November 2024

18

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells

28 November 2024

20

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits

28 November 2024

21

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome

28 November 2024

22

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

28 November 2024

23

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells

28 November 2024

24

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Modulation of IL-1 inflammatory and immunomodulatory properties by IL-6

28 November 2024

25

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

28 November 2024

26

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece

28 November 2024

27

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues

28 November 2024

28

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor

28 November 2024

29

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing

28 November 2024

30

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Processing of tumour necrosis factor-α precursor by metalloproteinases

28 November 2024

31

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

28 November 2024

32

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

An osmosensing signal transduction pathway in mammalian cells

28 November 2024

33

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells

28 November 2024

34

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist

28 November 2024

36

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

28 November 2024

40

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

28 November 2024

41

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Production of interleukin-1-receptor antagonist during experimental endotoxaemia

28 November 2024

45

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease

28 November 2024

46

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury

28 November 2024

47

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans

28 November 2024

48

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia.

28 November 2024

50

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

28 November 2024

51

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

In vivo evidence that the rise in plasma IL 6 following injection of a fever-inducing dose of LPS is mediated by IL 1 beta

28 November 2024

52

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

28 November 2024

54

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin 1 receptor blockade attenuates the host inflammatory response

28 November 2024

55

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits

28 November 2024

56

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy

28 November 2024

63

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis

28 November 2024

64

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans.

28 November 2024

66

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

28 November 2024

67

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody.

28 November 2024

68

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

28 November 2024

70

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality

28 November 2024

72

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis.

28 November 2024

73

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock

28 November 2024

74

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

28 November 2024

76

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

28 November 2024

77

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits

28 November 2024

78

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia

28 November 2024

79

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

28 November 2024

80

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study

28 November 2024

81

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

28 November 2024

82

1 reference

https://api.crossref.org/works/10.1378/CHEST.112.6_SUPPLEMENT.321S

28 November 2024

Identifiers

1 reference

6 October 2017

1 reference